drugset / Trial / NCT00659945

Aprepitant for PONV Prophylaxis in Outpatient Plastic Surgery

NCT00659945

RandomizedParallel-groupDouble-blindPrevention

Summary

Hypothesis: Aprepitant plus ondansetron is more effective than ondansetron plus placebo for prevention of postoperative emesis in patients at moderate-to-high risk for PONV for up to 48 hours after surgery. Specific Aim: To determine the incidence of PONV during the first 48 hours after surgery; in patients who have received aprepitant plus ondansetron versus ondansetron plus placebo for up to 48 hours after surgery.

Timeline

Start
2008-06
Primary completion
2009-11
Completion
2010-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Aprepitant Other / unclassified
Comparator Ondansetron Other / unclassified 4 mg Intravenous

Indications

No indication recorded.